PDF herunterladen
Drug Res (Stuttg) 2020; 70(02/03): 112-118
DOI: 10.1055/a-1085-2542
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Toxicity of Pioglitazone on Mitochondria Isolated from Brain and Heart: An Analysis for Probable Drug-Induced Neurotoxicity and Cardiotoxicity

Enaytollah Seydi
1   Department of Occupational Health and Safety Engineering, Alborz University of Medical Sciences, Karaj, Iran (the Islamic Republic of)
2   Research Center for Health, Safety and Environment, Alborz University of Medical Sciences, Karaj, Iran
,
Tina Servati
3   Department of Pharmacology and Toxicology, Shahid Beheshti University of Medical Science, Tehran, Iran (the Islamic Republic of)
,
Fatemeh Samiei
3   Department of Pharmacology and Toxicology, Shahid Beheshti University of Medical Science, Tehran, Iran (the Islamic Republic of)
,
Parvaneh Naserzadeh
3   Department of Pharmacology and Toxicology, Shahid Beheshti University of Medical Science, Tehran, Iran (the Islamic Republic of)
,
Jalal Pourahmad
3   Department of Pharmacology and Toxicology, Shahid Beheshti University of Medical Science, Tehran, Iran (the Islamic Republic of)
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 03. November 2019

accepted 16. Dezember 2019

Publikationsdatum:
13. Januar 2020 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Pioglitazone (PG) is one of the thiazolidinedione (TZDs) drugs used in diabetic patients. TZDs are known as peroxisome proliferator-activated receptor gamma (PPARγ) agonists. Mitochondria are considered as one of the targets of these drugs. The mechanisms of the effect of PG on mitochondria are not well understood. In this study, we investigated the effect of PG on mitochondria isolated from brain and heart. Mitochondrial parameters such as succinate dehydrogenase (SDH) activity, reactive oxygen species (ROS) generation, collapse in mitochondrial membrane potential (MMP), mitochondrial swelling and cytochrome c release were evaluated. The results showed that PG at concentrations of 12.5, 25 and 50 µg/ml increased the generation of ROS, the collapse of MMP, mitochondrial swelling and the release of cytochrome c in mitochondria isolated from both brain and heart tissues. The underlying mechanisms of PG induced neuro-toxicity and cardio-toxicity may be associated with changes in mitochondrial function, ROS generation (oxidative stress), and changes in the mitochondrial membrane.

Key words

pharmacology - toxicology - apoptosis
 

  • References

  • 1 Divakaruni AS, Wiley SE, Rogers GW. et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci USA 2013; 110: 5422-5427
    CrossrefPubMedGoogle Scholar
  • 2 Hu D, Wu CQ, Li ZJ. et al. Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria. Toxicol Appl Pharmacol 2015; 284: 134-141
    CrossrefPubMedGoogle Scholar
  • 3 Perez-Ortiz JM, Tranque P, Vaquero CF. et al. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 2004; 279: 8976-8985
    CrossrefPubMedGoogle Scholar
  • 4 Sanz MN, Sanchez-Martin C, Detaille D. et al. Acute mitochondrial actions of glitazones on the liver: A crucial parameter for their antidiabetic properties. Cell Physiol Biochem 2011; 28: 899-910
    CrossrefPubMedGoogle Scholar
  • 5 He H, Tao H, Xiong H. et al. Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor gamma-independent mitochondrial oxidative stress in mouse hearts. Toxicol Sci 2014; 138: 468-481
    CrossrefPubMedGoogle Scholar
  • 6 Skov V, Glintborg D, Knudsen S. et al. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. PLoS One 2008; 3: e2466
    CrossrefPubMedGoogle Scholar
  • 7 Giles TD, Miller AB, Elkayam U. et al. Pioglitazone and heart failure: Results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. Journal of Cardiac Failure 2008; 14: 445-452
    PubMedGoogle Scholar
  • 8 Liao H-W, Saver JL, Wu Y-L. et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 2017; 7: e013927
    CrossrefPubMedGoogle Scholar
  • 9 Nesto RW, Bell D, Bonow RO. et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948
    CrossrefPubMedGoogle Scholar
  • 10 Beheshti F, Hosseini M, Hashemzehi M. et al. The effects of PPAR-gamma agonist pioglitazone on hippocampal cytokines, brain-derived neurotrophic factor, memory impairment, and oxidative stress status in lipopolysaccharide-treated rats. Iran J Basic Med Sci 2019; 22: 940-948
    PubMedGoogle Scholar
  • 11 McGuire JL, Correll EA, Lowery AC. et al. Pioglitazone improves working memory performance when administered in chronic TBI. Neurobiol Dis 2019; 132: 104611
    CrossrefPubMedGoogle Scholar
  • 12 Quan Q, Qian Y, Li X. et al. Pioglitazone Reduces beta Amyloid Levels via Inhibition of PPARgamma Phosphorylation in a Neuronal Model of Alzheimer’s Disease. Front Aging Neurosci 2019; 11: 178
    CrossrefPubMedGoogle Scholar
  • 13 Pourahmad J, Hosseini MJ. Application of isolated mitochondria in toxicological and clinical studies. Iran J Pharm Res 2012; 11: 703-704
    PubMedGoogle Scholar
  • 14 Bova MP, Tam D, McMahon G. et al. Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol Lett 2005; 155: 41-50
    CrossrefPubMedGoogle Scholar
  • 15 Castro JP, Wardelmann K, Grune T. et al. Mitochondrial Chaperones in the Brain: Safeguarding Brain Health and Metabolism?. Front Endocrinol (Lausanne) 2018; 9: 196
    CrossrefPubMedGoogle Scholar
  • 16 Zhao Q, Sun Q, Zhou L. et al. Complex Regulation of Mitochondrial Function During Cardiac Development. J Am Heart Assoc 2019; 8: e012731
    PubMedGoogle Scholar
  • 17 Dello Russo C, Gavrilyuk V, Weinberg G. et al. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003; 278: 5828-5836
    CrossrefPubMedGoogle Scholar
  • 18 Sun L, Yuan Q, Xu T. et al. Pioglitazone improves mitochondrial function in the remnant kidney and protects against renal fibrosis in 5/6 nephrectomized rats. Front Pharmacol 2017; 8: 545
    CrossrefPubMedGoogle Scholar
  • 19 Masubuchi Y, Kano S, Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 2006; 222: 233-239
    CrossrefPubMedGoogle Scholar
  • 20 Quintanilla RA, Jin YN, Fuenzalida K. et al. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: Possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J Biol Chem 2008; 283: 25628-25637
    CrossrefPubMedGoogle Scholar
  • 21 Rachek LI, Yuzefovych LV, Ledoux SP. et al. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol Appl Pharmacol 2009; 240: 348-354
    CrossrefPubMedGoogle Scholar
  • 22 Rezaiean Mehrabadi A, Jamshidzadeh A, Rashedinia M. et al. Study of the effects of ATP suppliers and thiol reductants on toxicity of pioglitazone in isolated rat liver mitochondria. Iran J Pharm Res 2015; 14: 825-832
    PubMedGoogle Scholar
  • 23 Shannon CE, Daniele G, Galindo C. et al. Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes. Febs J 2017; 284: 451-465
    CrossrefPubMedGoogle Scholar
  • 24 Munro D, Treberg JR. A radical shift in perspective: Mitochondria as regulators of reactive oxygen species. J Exp Biol 2017; 220 1170-1180
    CrossrefPubMedGoogle Scholar
  • 25 Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009; 417: 1-13
    CrossrefPubMedGoogle Scholar
  • 26 Rigoulet M, Yoboue ED, Devin A. Mitochondrial ROS generation and its regulation: Mechanisms involved in H(2)O(2) signaling. Antioxid Redox Signal 2011; 14: 459-468
    CrossrefPubMedGoogle Scholar
  • 27 Zhao RZ, Jiang S, Zhang L. et al. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int J Mol Med 2019; 44: 3-15
    PubMedGoogle Scholar
  • 28 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976; 72: 248-254
    CrossrefPubMedGoogle Scholar
  • 29 Zhao Y, Ye L, Liu H. et al. Vanadium compounds induced mitochondria permeability transition pore (PTP) opening related to oxidative stress. J Inorg Biochem 2010; 104: 371-378
    CrossrefPubMedGoogle Scholar
  • 30 Salimi A, Eybagi S, Seydi E. et al. Toxicity of macrolide antibiotics on isolated heart mitochondria: A justification for their cardiotoxic adverse effect. Xenobiotica 2016; 46: 82-93
    CrossrefPubMedGoogle Scholar
  • 31 Baracca A, Sgarbi G, Solaini G. et al. Rhodamine 123 as a probe of mitochondrial membrane potential: Evaluation of proton flux through F(0) during ATP synthesis. Biochim Biophys Acta 2003; 1606: 137-146
    PubMedGoogle Scholar
  • 32 Hsiao PJ, Chiou HC, Jiang HJ. et al. Pioglitazone enhances cytosolic lipolysis, beta-oxidation and autophagy to ameliorate hepatic steatosis. Sci Rep 2017; 7: 9030
    CrossrefPubMedGoogle Scholar
  • 33 Picard M, McEwen BS. Mitochondria impact brain function and cognition. Proc Natl Acad Sci USA 2014; 111: 7-8
    CrossrefPubMedGoogle Scholar
  • 34 Rango M, Bresolin N. Brain Mitochondria, Aging, and Parkinson’s Disease. Genes (Basel) 2018; 9: 5
    PubMedGoogle Scholar
  • 35 Griffiths EJ. Mitochondria and heart disease. Adv Exp Med Biol 2012; 942: 249-267
    PubMedGoogle Scholar
  • 36 Siasos G, Tsigkou V, Kosmopoulos M. et al. Mitochondria and cardiovascular diseases-from pathophysiology to treatment. Ann Transl Med 2018; 6: 256
    CrossrefPubMedGoogle Scholar
  • 37 Dan Dunn J, Alvarez LA, Zhang X. et al. Reactive oxygen species and mitochondria: A nexus of cellular homeostasis. Redox Biol 2015; 6: 472-485
    CrossrefPubMedGoogle Scholar
  • 38 Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell 2012; 48: 158-167
    CrossrefPubMedGoogle Scholar
  • 39 Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 2014; 94: 909-950
    CrossrefPubMedGoogle Scholar
  • 40 Nissanka N, Moraes CT. Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease. FEBS Lett 2018; 592: 728-742
    CrossrefPubMedGoogle Scholar
  • 41 Seydi E, Rasekh HR, Salimi A. et al. Selective toxicity of apigenin on cancerous hepatocytes by directly targeting their mitochondria. Anticancer Agents Med Chem 2016; 16: 1576-1586
    CrossrefPubMedGoogle Scholar
  • 42 Stefanatos R, Sanz A. The role of mitochondrial ROS in the aging brain. FEBS Lett 2018; 592: 743-758
    CrossrefPubMedGoogle Scholar
  • 43 Gottlieb E, Armour SM, Harris MH. et al. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ 2003; 10: 709-717
    CrossrefPubMedGoogle Scholar